Orthofix Medical Inc. logo

OFIX Earnings Date: Nov 9, 2026 (Estimated) — Orthofix Medical Inc.

NASDAQ · Healthcare · Medical Devices

Updated

Price $9.62
Market Cap $391.8M
P/E -6.4
52W Range $8.50 – $16.99
Next Earnings · Before open (est.)

When is OFIX's next earnings date?

Orthofix Medical Inc. (OFIX) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.11 on revenue of $210.5M.

How did OFIX do in its last earnings report?

In its most recent report on Aug 5, 2026 (Q2 2026), Orthofix Medical Inc. posted EPS of $0.07 versus the -$0.41 estimate, a beat of 158.3%. Revenue was $210.9M against a $209.3M estimate. The stock's 1-day post-earnings move was -14.6%.

How much does OFIX stock move after earnings?

OFIX beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.7% (up or down) in the day after earnings.

About Orthofix Medical Inc.

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.

Earnings History

DatePeriodEPS Est.EPS Act.SurpriseRevenueResult1D Δ1W Δ1M Δ
2026-08-05Q2 2026-0.410.07+158.33%$210.9M✅ Beat-14.59%-15.41%-23.11%
2026-05-05Q1 2026-0.38-0.13+65.79%$196.7M✅ Beat+3.58%-2.83%-19.07%
2026-02-24Q4 20250.120.24+100.00%$219.9M✅ Beat-6.18%-1.62%-13.76%
2025-11-04Q3 2025-0.180.20+211.11%$205.6M✅ Beat-7.41%-6.41%-0.87%
2025-08-05Q2 2025-0.150.13+186.67%$203.1M✅ Beat+13.46%+19.26%+35.94%
2025-02-25Q4 2024-0.050.02+140.00%$215.7M✅ Beat-3.53%-6.45%-9.04%
2024-11-07Q3 2024-0.150.07+146.67%$196.6M✅ Beat-0.98%+1.30%+1.20%
2024-08-06Q2 2024-0.190.05+126.32%$198.6M✅ Beat+19.53%+9.94%+13.78%

Showing last 8 quarters.

Revenue by segment & region

By region

Q2 FY26 · $37.2M total

SegmentShareRevenueYoY
Other Countries63.7%$23.7M+46.5%
ITALY16.1%$6.0M+6.3%
FRANCE8.8%$3.3M+2.6%
GERMANY6.2%$2.3M+2.2%
BRAZIL5.2%$1.9M+94.1%

Source: company filings via FMP. YoY compares the same fiscal period a year earlier.

Related Companies

Learn More

Explore More

Financial data from licensed market-data providers; risk factors from SEC EDGAR filings. AI-powered analysis. Data last updated .